Stay updated on Pembrolizumab vs Standard Chemo in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Standard Chemo in Metastatic Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab vs Standard Chemo in Metastatic Melanoma Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has been updated to include new information about the study of pembrolizumab in treating metastatic melanoma, including details on laboratory biomarker analysis and quality-of-life assessments. Additionally, the principal investigator's name has been clarified, and the revision number has been updated.SummaryDifference55%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 15, 2025.SummaryDifference0.4%
- Check37 days agoChange DetectedThe page has updated its versioning information, moving from Revision v2.14.2 to v2.14.3, and has changed the date of the last update from January 15, 2025, to March 25, 2025.SummaryDifference0.3%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.9%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.9%
Stay in the know with updates to Pembrolizumab vs Standard Chemo in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Standard Chemo in Metastatic Melanoma Clinical Trial page.